Hofman et al. recently published a first-in-human study looking at the safety, imaging, and dosimetry of a CAIX-targeting peptide, 68Ga DPI-4452, in patients with clear cell renal cell carcinoma [66]. The gene discussed is CA9; the disease is clear cell renal carcinoma.